Scholarlink

Objective <p>Parkinson’s disease (PD) is frequently associated with orthostatic hypotension (OH). Research on the prevalence of OH in PD and its effects on patients has produced inconsistent findings.</p> Methods <p>A systematic review and meta-analysis were conducted by searching for studies related to PD and OH in the PubMed, Web of Science, Embase, and Cochrane databases. Data were pooled as necessary to calculate the prevalence of OH in patients with PD, along with odds ratios (OR), weighted mean differences (WMD), or standardized mean differences (SMD) with 95% confidence intervals (CI). Heterogeneity was assessed using the <i>I</i><sup>2</sup> statistic.</p> Results <p>The prevalence of OH in patients with PD was found to be 33.1% (95% CI 29.3–37%) in a pooled sample of 7748 subjects. Patients with PD and OH were significantly older at the time of examination (WMD 2.92&#xa0;years) and had a longer disease duration (WMD 0.71&#xa0;years) compared with those without OH. There was no significant difference in the distribution of sex, or in the scores of the Unified Parkinson’s Disease Rating Scale (UPDRS)/the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) parts I and II, as well as the total scores among patients with Parkinson’s disease with or without OH. In addition, patients with PD and OH exhibited significantly higher UPDRS/MDS-UPDRS scores across part III section scores (SMD 0.41, 95% CI 0.23–0.59).</p> Conclusions <p>The prevalence of OH in PD is 33.1%. Patients with PD and OH are generally older at examination, have a longer disease duration, and display more severe motor symptoms compared with those without OH.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence and impact of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年7月26日

查看全文
  • Hui Wang,
  • Chi Zhang,
  • Dongxun Xu

摘要

Objective

Parkinson’s disease (PD) is frequently associated with orthostatic hypotension (OH). Research on the prevalence of OH in PD and its effects on patients has produced inconsistent findings.

Methods

A systematic review and meta-analysis were conducted by searching for studies related to PD and OH in the PubMed, Web of Science, Embase, and Cochrane databases. Data were pooled as necessary to calculate the prevalence of OH in patients with PD, along with odds ratios (OR), weighted mean differences (WMD), or standardized mean differences (SMD) with 95% confidence intervals (CI). Heterogeneity was assessed using the I2 statistic.

Results

The prevalence of OH in patients with PD was found to be 33.1% (95% CI 29.3–37%) in a pooled sample of 7748 subjects. Patients with PD and OH were significantly older at the time of examination (WMD 2.92 years) and had a longer disease duration (WMD 0.71 years) compared with those without OH. There was no significant difference in the distribution of sex, or in the scores of the Unified Parkinson’s Disease Rating Scale (UPDRS)/the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) parts I and II, as well as the total scores among patients with Parkinson’s disease with or without OH. In addition, patients with PD and OH exhibited significantly higher UPDRS/MDS-UPDRS scores across part III section scores (SMD 0.41, 95% CI 0.23–0.59).

Conclusions

The prevalence of OH in PD is 33.1%. Patients with PD and OH are generally older at examination, have a longer disease duration, and display more severe motor symptoms compared with those without OH.